Alzheimer's disease (AD) causes cognitive function disorder and has become the preeminent cause of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists, semaglutide, have shown positive effects on promoting the cognitive function. However, research about the mechanism of semaglutide as a therapeutic intervention in AD is sparse.
Objective
This study was to investigate the therapeutic efficacy of semaglutide in a transgenic mouse model of AD pathology and explored the detailed mechanism by semaglutide modulated neuroinflammatory processes.
Methods
Male amyloid precursor protein/presenilin 1 (APP/PS1) transgenic mice were treated with semaglutide or vehicle for 8 weeks. Morris water maze test was used to assess the therapeutic efficacy of semaglutide on recognition function. Pathology analysis was performed to detect the deposition of amyloid plaques. High-throughput sequencing analysis was applied to specify the mechanism. Microglia and astrocyte activation were assessed with immunofluorescent staining. Inflammation cytokine levels were evaluated with enzyme-linked immunosorbent assay (ELISA). Related proteins and pathway were evaluated with western blot.
Results
Semaglutide treatment attenuated Aβ accumulation and enhanced cognitive function in APP/PS1 transgenic mice. Through transcriptomic profiling, immunohistochemical staining, and ELISA, semaglutide was substantiated to inhibit the overactivation of microglia and astrocytes, as well as to curtail the secretion of inflammatory mediators. Furthermore, semaglutide robustly activated AMP-activated protein kinase (AMPK) and suppressed the toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB) signaling cascade, thus reducing the Aβ deposition and dampening the inflammatory cascade.
Conclusions
The results demonstrated that semaglutide mitigated neuroinflammation and decelerated the advance of AD in APP/PS1 transgenic mice.
ScheltensPDe StrooperBKivipeltoM, et al.Alzheimer's disease. Lancet2021; 397: 1577–1590.
2.
LongJMHoltzmanDM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell2019; 179: 312–339.
3.
ScheltensPBlennowKBretelerMM, et al.Alzheimer's disease. Lancet2016; 388: 505–517.
4.
MastersCLBatemanRBlennowK, et al.Alzheimer's disease. Nat Rev Dis Primers2015; 1: 15056.
5.
SelfWKHoltzmanDM. Emerging diagnostics and therapeutics for Alzheimer disease. Nat Med2023; 29: 2187–2199.
6.
NandiACountsNChenS, et al.Global and regional projections of the economic burden of Alzheimer's disease and related dementias from 2019 to 2050: a value of statistical life approach. EClinicalMedicine2022; 51: 101580.
7.
JuckerMWalkerLC. Alzheimer's disease: from immunotherapy to immunoprevention. Cell2023; 186: 4260–4270.
8.
JagustWJTeunissenCEDeCarliC. The complex pathway between amyloid beta and cognition: implications for therapy. Lancet Neurol2023; 22: 847–857.
9.
KarranEDe StrooperB. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov2022; 21: 306–318.
10.
CarroETrejoJLGomez-IslaT, et al.Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med2002; 8: 1390–1397.
11.
De FeliceFGGoncalvesRAFerreiraST. Impaired insulin signalling and allostatic load in Alzheimer disease. Nat Rev Neurosci2022; 23: 215–230.
12.
BrandeburaANPaumierAOnurTS, et al.Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders. Nat Rev Neurosci2023; 24: 23–39.
13.
LeeHGWheelerMAQuintanaFJ. Function and therapeutic value of astrocytes in neurological diseases. Nat Rev Drug Discov2022; 21: 339–358.
14.
LaurindoLFBarbalhoSMGuiguerEL, et al.GLP-1a: Going beyond traditional use. Int J Mol Sci2022; 23: 739.
15.
CarusoICignarelliALaviolaL, et al.GLP-1 receptor agonists for cardiovascular protection: a matter of time. Diabetes Care2022; 45: e30–e31.
16.
BergmannNCDaviesMJLingvayI, et al.Semaglutide for the treatment of overweight and obesity: a review. Diabetes Obes Metab2023; 25: 18–35.
17.
KnudsenLBLauJ. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne)2019; 10: 155.
18.
Diz-ChavesYHerrera-PerezSGonzalez-MatiasLC, et al.Glucagon-like peptide-1 (GLP-1) in the integration of neural and endocrine responses to stress. Nutrients2020; 12: 3304.
19.
ColinIMSzczepanskiLWGerardAC, et al.Emerging evidence for the use of antidiabetic drugs, glucagon-like peptide 1 receptor agonists, for the treatment of Alzheimer's disease. touchREV Endocrinol2023; 19: 16–24.
20.
EdisonPFemminellaGDRitchieCW, et al.Evaluation of liraglutide in the treatment of Alzheimer's disease. Alzheimers Dement2021; 17: e057848.
21.
YoungKMorrisonH. Quantifying microglia morphology from photomicrographs of immunohistochemistry prepared tissue using ImageJ. J Vis Exp2018; 136: 57648.
22.
LeeYMorrisonBMLiY, et al.Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature2012; 487: 443–448.
23.
DeppCSunTSasmitaAO, et al.Myelin dysfunction drives amyloid-beta deposition in models of Alzheimer's disease. Nature2023; 618: 349–357.
24.
DasSLiZWachterA, et al.Distinct transcriptomic responses to Abeta plaques, neurofibrillary tangles, and APOE in Alzheimer's disease. Alzheimers Dement2024; 20: 74–90.
25.
YangFZhaoDChengM, et al.mTOR-mediated immunometabolic reprogramming nanomodulators enable sensitive switching of energy deprivation-induced microglial polarization for Alzheimer's disease management. ACS Nano2023; 17: 15724–15741.
26.
SunNVictorMBParkYP, et al.Human microglial state dynamics in Alzheimer's disease progression. Cell2023; 186: 4386–4403 e4329.
27.
ChenXFirulyovaMManisM, et al.Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy. Nature2023; 615: 668–677.
28.
BellaverBPovalaGFerreiraPCL, et al.Astrocyte reactivity influences amyloid-beta effects on tau pathology in preclinical Alzheimer's disease. Nat Med2023; 29: 1775–1781.
29.
ArranzAMDe StrooperB. The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications. Lancet Neurol2019; 18: 406–414.
30.
HaselPAisenbergWHBennettFC, et al.Molecular and metabolic heterogeneity of astrocytes and microglia. Cell Metab2023; 35: 555–570.
31.
DuttaDJanaMPaidiRK, et al.Tau fibrils induce glial inflammation and neuropathology via TLR2 in Alzheimer’s disease–related mouse models. J Clin Invest2023; 133: e161987.
32.
LianHYangLColeA, et al.NFκB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer’s disease. Neuron2015; 85: 101–115.
33.
MironJPicardCLafaille-MagnanMÉ, et al.Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation. Alzheimers Dement2019; 15: 951–960.
34.
WangZJLiXRChaiSF, et al.Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/ GLUT4 pathway. Neuropharmacology2023; 240: 109716.
35.
Garcia-CasaresNGonzalez-GonzalezGde la Cruz-CosmeC, et al.Effects of GLP-1 receptor agonists on neurological complications of diabetes. Rev Endocr Metab Disord2023; 24: 655–672.
36.
BirajdarSVMazahirFAlamMI, et al.Repurposing and clinical attributes of antidiabetic drugs for the treatment of neurodegenerative disorders. Eur J Pharmacol2023; 961: 176117.
37.
LiuTZhangLMeiW. CTRP9 Attenuates peripheral nerve injury-induced mechanical allodynia and thermal hyperalgesia through regulating spinal microglial polarization and neuroinflammation mediated by AdipoR1 in male mice. Cell Biol Toxicol2024; 40: 91.
38.
DruckerDJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov2020; 19: 277–289.
39.
RyanDH. Semaglutide for obesity: four STEPs forward, but more to come. Lancet Diabetes Endocrinol2021; 9: 252–254.
40.
MullerTDFinanBBloomSR, et al.Glucagon-like peptide 1 (GLP-1). Mol Metab2019; 30: 72–130.
41.
AthaudaDMaclaganKSkeneSS, et al.Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet2017; 390: 1664–1675.
42.
LevitanDGreenwaldI. Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature1995; 377: 351–354.
43.
BaeCSSongJ. The role of glucagon-like peptide 1 (GLP1) in type 3 diabetes: GLP-1 controls insulin resistance, neuroinflammation and neurogenesis in the brain. Int J Mol Sci2017; 18: 2493.
44.
ZhengJXieYRenL, et al.GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer's disease. Mol Metab2021; 47: 101180.
45.
ChenJShiZZhangC, et al.Oroxin A alleviates early brain injury after subarachnoid hemorrhage by regulating ferroptosis and neuroinflammation. J Neuroinflammation2024; 21: 116.
46.
ChenJWangYLiM, et al.Netrin-1 alleviates early brain injury by regulating ferroptosis via the PPARgamma/Nrf2/GPX4 signaling pathway following subarachnoid hemorrhage. Transl Stroke Res2024; 15: 219–237.
47.
MecaADBobocIKSMititelu-TartauL, et al.Unlocking the potential: semaglutide's impact on Alzheimer's and Parkinson's disease in animal models. Curr Issues Mol Biol2024; 46: 5929–5949.
48.
BalducciCFrascaAZottiM, et al.Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by β-amyloid oligomers in an acute mouse model of Alzheimer's disease. Brain Behav Immun2017; 60: 188–197.
49.
Calvo-RodriguezMGarcía-RodríguezCVillalobosC, et al.Role of toll like receptor 4 in Alzheimer's disease. Front Immunol2020; 11: 1588.
